Export 8 results:
Author Title [ Type(Desc)] Year
Filters: Keyword is Serum Albumin  [Clear All Filters]
Journal Article
F. Zsila, Molnár, P., and Deli, J., Analysis of binding interaction between the natural apocarotenoid bixin and human serum albumin by circular dichroism and fluorescence spectroscopy., Chem Biodivers, vol. 2, no. 6, pp. 758-72, 2005.
F. Zsila, Circular dichroism spectroscopic detection of ligand binding induced subdomain IB specific structural adjustment of human serum albumin., J Phys Chem B, vol. 117, no. 37, pp. 10798-806, 2013.
F. Zsila and Fitos, I., Combination of chiroptical, absorption and fluorescence spectroscopic methods reveals multiple, hydrophobicity-driven human serum albumin binding of the antimalarial atovaquone and related hydroxynaphthoquinone compounds., Org Biomol Chem, vol. 8, no. 21, pp. 4905-14, 2010.
F. Zsila, Bikadi, Z., Malik, D., Hari, P., Pechan, I., Berces, A., and Hazai, E., Evaluation of drug-human serum albumin binding interactions with support vector machine aided online automated docking., Bioinformatics, vol. 27, no. 13, pp. 1806-13, 2011.
C. Domonkos, Fitos, I., Visy, J., and Zsila, F., Fatty acid modulated human serum albumin binding of the β-carboline alkaloids norharmane and harmane., Mol Pharm, vol. 10, no. 12, pp. 4706-16, 2013.
C. Domonkos, Fitos, I., Visy, J., and Zsila, F., Role of the conformational flexibility of evodiamine in its binding to protein hosts: a comparative spectroscopic and molecular modeling evaluation with rutaecarpine., Phys Chem Chem Phys, vol. 16, no. 41, pp. 22632-42, 2014.
D. B. Horváthy, Vácz, G., Szabó, T., Szigyártó, I. Cs., Torõ, I., Vámos, B., Hornyák, I., Renner, K., Klára, T., Szabó, B. T., Dobõ-Nagy, C., Doros, A., and Lacza, Z., Serum albumin coating of demineralized bone matrix results in stronger new bone formation, Journal of Biomedical Materials Research - Part B Applied Biomaterials, vol. 104, no. 1, pp. 126 - 132, 2016.
F. Zsila, Subdomain IB is the third major drug binding region of human serum albumin: toward the three-sites model., Mol Pharm, vol. 10, no. 5, pp. 1668-82, 2013.